

## Primary Hyperparathyroidism Committee meeting 8

**Date:** 20/04/2018

**Location:** NGC Boardroom

**Minutes:** Confirmed

<b>Committee members present:</b>		
Jonathan Mant (Chair) (JM)		(Present for notes 1 – 4)
Terry Aspray (TA)		(Present for notes 1 – 4)
Parijat De (PD)		(Present for notes 1 – 4)
Joy Foster (JF)		(Present for notes 1 – 4)
Neil Gittoes (NG)		(Present for notes 1 – 4)
Imran Jawaid (IJ)		(Present for notes 1 – 4)
Fausto Palazzo (FP)		(Present for notes 1 – 4)
Peter Selby (PS)		(Present for notes 1 – 4)
Anthony Skene (AS)		(Present for notes 1 – 4)
Nicholas Thomson (NT)		(Present for notes 1 – 4)

<b>In attendance:</b>		
Katie Broomfield (KB)	Project Manager	(Present for notes 1 – 4)
Emma Cowles (EC)	Senior Health Economist	(Present for notes 1 – 4)
Sharangini Rajesh (SR)	Research Fellow	(Present for notes 1 – 4)
Sharon Swain (SS)	Associate Director/Guideline Lead	(Present for notes 1 – 4)
Emily Terrazas-Cruz (ETC) (by phone)	Senior Research Fellow	(Present for notes 1 – 4)
Melina Vasileiou	Research Fellow	(Present for notes 1 – 4)
Kyann Zhang (KZ)	Health Economist	(Present for notes 1 – 4)

<b>Apologies:</b>	
Julie Cox (JC)	Guideline Committee
Jill Cobb (JC)	Information Specialist, NGC
Judith McBride (JMB)	Senior Medical Editor, NICE
Nick Staples (NS)	Guideline Commissioning Manager, NICE

## 1. Welcome and objectives for the meeting

The Chair welcomed the Committee members and attendees to the eighth meeting on primary hyperparathyroidism.

The Chair informed the Committee that apologies had been received. These are noted above.

The Chair outlined the objectives of the meeting.

## Introductions

## 2. Confirmation of matter under discussion, and declarations of interest

The Chair asked everyone to declare verbally any interests that have arisen since application. The following new interest was received for this meeting:

### Committee Declarations of Interest

N.B. The Chair and Committee members were recruited to this guideline using NICE DOI policy published April 2018.

Insert initials	Declaration	Classification (as per the NICE DOI policy wording*)	Chair's action
TA	<p>Advice given to UCB Pharmaceuticals on osteoporosis therapies (not related to primary hyperparathyroidism).</p> <p>There were two components to this project:</p> <ol style="list-style-type: none"><li>1. Advising the company (which does not currently market osteoporosis treatments) about routine care for osteoporosis including ALL treatments: bisphosphonates, denosumab and teriparatide</li><li>2. The potential for their new agent (romosozumab: A sclerostin antibody) in treating osteoporosis</li></ol> <p>While we have discussed in</p>	Direct financial non-specific	No action other than the process of open declaration

	<p>the committee the role of bisphosphonates in the management of PHPT, this is not a topic which is relevant to my work with UCB.</p>		
<p>NICE DOI policy classifications are:</p> <ul style="list-style-type: none"> <li>• Direct financial specific</li> <li>• Direct financial non-specific</li> <li>• Direct non-financial specific</li> <li>• Direct non-financial non-specific</li> <li>• Indirect financial specific</li> <li>• Indirect financial non-specific</li> </ul>			
<p>The DOI register was made available to the Committee chair. The chair reviewed the DOI register and deemed that one of the original DOIs were in conflict with the agenda topics and clinical questions under discussion at the meeting. FP was partially excluded from items 3.4 and 3.6 during the discussion of recommendations, with the chair exercising discretion.</p>			
<p><b>3. Presentations and discussion</b></p>			
<p>3.1 KZ led a discussion on health economics.</p> <p>3.2 SR presented the updated evidence review for monitoring. The committee drafted recommendations.</p> <p>3.3 SS led a discussion on the draft recommendations for diagnostic tests. The committee updated the draft recommendations.</p> <p>3.4 JM led a discussion on the draft recommendations for surgical interventions. The committee updated the draft recommendations.</p> <p>3.5 JM led a discussion on the discussion section for patient information.</p> <p>3.6 JM led a discussion on the draft recommendations for surgical indications. The committee updated the draft recommendations.</p>			
<p><b>4. Any other business</b></p> <p>The group discussed next steps and agreed action points.</p>			

**Date of next meeting:** 04/06/2018

**Location of next meeting:** Royal College of Physicians